2017 Randox Health Grand National Trophy Statue unveiled at Aintree Racecourse

Home - Research - Page 3

2017 Randox Health Grand National Trophy Statue unveiled at Aintree Racecourse

A giant replica of the 2017 Randox Health Grand National trophy is being installed at Aintree Racecourse ahead of the world’s greatest horse race. The design was unveiled for the first time today during the Northern media lunch.

The statue standing at almost 6 meters, which will be seen by over 600 million people during the three day festival, depicts the same level of detail as the real trophy. The stunning piece is solid silver gilded with gold, and depicts horses galloping through strands of DNA.

A spot will be marked out near the statute directing race-goers where to stand to get a picture of them ‘holding’ the trophy. It is part of Randox Health’s plan to get the nation to #FeelLikeAWinner during the festival, even if they won’t be at Aintree. They hope people at the racecourse will share the trophy images on social media with people at home posting selfies with their cherished trophies!

Dr. Peter FitzGerald, Founder and Managing Director of Randox Health, commented;

“With the Randox Health Grand National being the greatest horse race in the world we wanted to give everyone a chance to feel like a winner throughout the festival. We’re very proud of the trophy and its one people can enjoy too. We want to give everybody the opportunity to feel part of this year’s festival even if they’re not here, which is why we’re encouraging them to share their own trophy selfies with the racing fans at Aintree. The Randox Health Grand National is a national occasion we want to share and we hope that we can encourage that.”

John Baker, Managing Director for Aintree Racecourse, commented;

“We’re delighted and honoured to work with Randox as a long term partner and we look forward to many years of success. With less than three weeks to go until the Randox Health Grand National Festival, we’re in great shape with the Aintree site looking tremendous and ticket sales going very well. We’re anticipating three days of thrilling racing with high quality entries and we look forward to plenty of fun and excitement off the track as well. The Aintree and Randox teams are working extremely hard to put on the best possible experience for our racegoers so we look forward to opening the gates on Thursday 6 April and welcoming everyone for a fantastic three days.”

The official reveal of the trophy statue has come after the announcement that for each of its five years of sponsorship, Randox Health, the title partner of the Randox Health Grand National, will create a unique winner’s trophy, and each member of the winning team – trainer, jockey and groom – will receive their own trophy in recognition of the teamwork that goes into achieving such monumental success.

The coveted trophy was unveiled by Sir Anthony McCoy and Dr Peter FitzGerald at the Weights Evening Reception at the Victoria and Albert Museum in London.

For more information about Randox Health Grand National Horse please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com


Randox Biosciences and Dana-Farber Cancer Institute Celebrate Success of Transatlantic Partnership

Today, Randox Biosciences and Dana Farber Cancer Institute highlighted the milestones achieved during their joint partnership. The collaborative partnership was the focus of the Boston-Ireland Precision Medicine Seminar with partners the City of Boston and the Massachusetts Life Science Center (MLSC).

The City of Boston Office of Economic Development and the Massachusetts Life Science Center are collaborating with Randox Biosciences on an innovative event to discuss the Boston-Ireland linkage in the field of Precision Medicine. The event will build business and science relationships between leading life science organizations. The program will highlight Boston as a global life science hub and illustrate why global leaders like Randox are seeking to build business partnerships in the area.

“Dana-Farber is a world-renowned name in the field of oncology and it is great to be working on this exciting new technology which is being developed in the lab of Dr. Novina.”  Marshall Dunlop of Randox Laboratories said.

In the last year, the clinical diagnostics and life sciences provider Randox Laboratories has established a collaborative agreement with Dr. Carl Novina at the Dana-Farber Cancer Institute and Harvard Medical School. The goal of this collaboration is to develop therapeutic antibodies that will be incorporated into a platform technology that can reprogram patients’ immune systems to attack cancers.

“I am excited to work with Randox and use these important antibody technologies to help develop a novel cancer therapy that could potentially make a real difference for cancer patients.” said Dr. Carl Novina, Dana Farber Cancer Institute.

The Randox BioSciences and Dana Farber relationship highlights the close ties between Boston, Massachusetts and Ireland and provides another example of the strengths of Boston and Ireland in the life sciences sector.  The life sciences industry continues to thrive all across Boston, from Longwood Medical Area – a world-famous medical campus with over 43,000 scientists, researchers, and staff including over 19,000 students – to the South Boston Waterfront District, the city’s newest cluster of high tech research, development, and manufacturing firms.

The City of Boston Chief of Economic Development John Barros said,Mayor Martin J. Walsh is proud of Boston’s historic links with Ireland and the diverse economic bridges these links have created today. Within the life sciences alone, our researchers and businesses work together in new ways every day to shape how we treat, cure, and innovate together. By partnering with Randox and other leaders in the field, we continue to tackle global challenges together. Here at the City of Boston, we are committed to maintaining open doors as a global and welcoming city. These international partnerships will continue to play an active role in fostering opportunities for collaboration and growth.”

“Collaboration is the key ingredient that makes Massachusetts the best place in the world to innovate,” said Travis McCready, President & CEO of the MLSC.  “It is great to see Randox collaborating with the leading scientists at the Dana-Farber Cancer Institute, toward the development of improved, targeted treatments for cancer patients.”

For more information about the Precision Medicine Seminar in Boston please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com


New Randox project committed to helping bladder cancer patients

Scientists at global healthcare company Randox, recently unveiled as the sponsors for The Grand National 2017 under the banner of Randox Health, today announced the company has been awarded an Innovate UK research award, for their pioneering work in the development of a diagnostic test for the detection of bladder cancer in haematuria patients.

The urine-based test is being developed in collaboration with The Belfast Trust and Queen’s University Belfast, and has been described by the project’s Lead Scientist at Randox, Dr Mark Ruddock, as the “holy grail” of diagnostic tests to stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer;

“Currently, all haematuria patients are ‘red-flagged’ as candidates for an invasive procedure called a cystoscopy (a camera inserted into the bladder), which is both embarrassing and uncomfortable for the patient.    In comparison, the revolutionary Randox test is based on a simple urine sample so is non-invasive and much more comfortable for the patient.”

 Considering less than 20% of patients with visible haematuria, and less than 5% with invisible haematuria are found to have bladder cancer,   Dr Ruddock highlighted the urgent need for a test that can inform decisions for patients who present with haematuria;

“In the UK, over £33.5 million is spent each year managing patients with haematuria who are subsequently found not to have bladder cancer.  As such, haematuria is a significant healthcare burden, which is only set to increase because of our aging population.  Use of this new test will allow urology teams the opportunity to reduce the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, and stratify patients identified as ‘high risk’.  This will result in significant healthcare savings, and an improvement in the waiting times for haematuria patients who do require diagnostic services ie. those patients deemed ‘high-risk’.”

Randox was successful in winning funding for phase one of the project, which has enabled an economic study to be carried out by The National Institute for Health Research Diagnostic Evidence Co-Operative Leeds who will investigate the economic benefits of the new diagnostic test for The National Health Service, and its role in the current patient care pathway.  On successful completion of phase one, Randox will be eligible to apply for phase two funding.

Professor Peter Selby, Professor of Cancer Medicine at the University of Leeds, and Director of the NIHR Diagnostic Evidence Cooperative Leeds, said:

“Bladder cancer is a very important disease which can be life threatening but also in many patients it can generate great anxiety, frequent hospital visits and many investigations. The new approach being developed by Randox has the potential to save lives and improve the quality of lives of many people at risk of bladder cancer.”

“Diagnostic Classifier for risk stratification of haematuria patients” was selected by Innovate UK in the “Stratified Medicine: connecting the UK infrastructure” competition.

New Randox project committed to helping bladder cancer patients

Evidence Immunoassay Control

Therapeutic Drug Quality Control

Multi-analyte immunoassay control designed for use in the routine monitoring of the Randox Fertility, Thyroid and Tumour Marker Arrays.

Features & Benefits

  • Lyophilised for enhanced stability
  • Assayed values available for Randox Biochip systems
  • 100% human serum
  • Stable to expiry date at 2oC – 8oC
  • Reconstituted stability of 7 days at 2oC – 8oC or 4 weeks at -20oC
DescriptionSizeAnalytesCat No 
Evidence Immunoassay Control 4 x 3 x 5ml14EV3570
Serum Diluent 20 x 5mlN/AMS5007

Analytes

  • CEA
  • Estradiol
  • FSH
  • Free T4
  • Free T3
  • Leutinising Hormone
  • Prolactin
  • Progesterone
  • PSA (Total)
  • PSA (Free)
  • Testosterone
  • Total T4
  • Total T3
  • TSH

Cardiac Array Quality Control

Therapeutic Drug Quality Control

Multi-analyte cardiac control designed for use in the routine monitoring of accuracy and precision on clinical chemistry and immunoassay systems. This is the only control of its type to include the novel marker heart type fatty acid binding protein (H-FAP). Three levels of control are supplied spanning the complete clinical range.

Features & Benefits

  • Lyophilised for enhanced stability
  • Assayed values available for Randox Biochip systems
  • 100% human serum
  • Stable to expiry at 2oC – 8oC
  • Reconstituted stability of 16 hours at 2oC – 8oC or 7 weeks at -80oC
DescriptionSizeAnalytesCat No 
Cardiac Array Control3 x 3 x 1ml4 EV3691

Analytes

  • Heart-type acid binding protein (H-FABP)
  • Myoglobin (MYO)
  • Troponin I (cTnI)
  • Creatine-Kinase Muscle Brain (CK-MB)

Not for sale in the USA


Synthetic Steroids Quality Control

Therapeutic Drug Quality Control

Human based quality control designed for use in the routine monitoring of both accuracy and precision. Assayed target values and ranges are provided for 5 different synthetic steroids.

Features & Benefits

  • Lyophilised for enhanced stability
  • 100% human material
  • Stable to expiry date at 2°C – 8°C
  • Reconstituted stability of 3 days at 2°C – 8°C or 14 days at -20°C
  • Assayed values available for Randox Biochip systems
DescriptionSizeAnalytesCat No 
Synthetic Steroids Control3 x 1ml5EV3709

Analytes

  • Methyltestosterone
  • Methandriol
  • 17 Beta Clostebol
  • Ethinylestradiol
  • Gestagens (Generic)

Metabolic Syndrome Array I Quality Control

Therapeutic Drug Quality Control

A multi-analyte quality control with target values and ranges provided for 9 parameters associated with metabolic syndrome.

Features & Benefits

  • Lyophilised for enhanced stability
  • 100% human material
  • Stable to expiry date at 2oC – 8oC
  • Reconstituted stability of 72 hours at 2oC – 8oC and 7 days at -20°C
  • Assayed values available for Randox Biochip systems
DescriptionSizeAnalytesCat No 
Metabolic Syndrome Array I Controls3 x 3 x 1ml9EV3757

Analytes

  • C-Peptide
  • Ferritin
  • Interleukin-6
  • Insulin
  • Interleukin-1α
  • Tumour Necrosis Factor α
  • Leptin
  • Plasminogen Activator Inhibitor-1
  • Resistin

Growth Promoter Quality Control

Therapeutic Drug Quality Control

A multi-analyte quality control provided with accurately assigned target values and ranges for 9 different growth promoters.

Features & Benefits

  • Lyophilised for enhanced stability
  • Stable to expiry date at 2oC – 8oC
  • Reconstituted stability of 14 days at 2oC – 8oC
  • Assayed values available for Randox Biochip systems
DescriptionSizeAnalytesCat No 
Growth Promoter Control3 x 1ml9GP5003

Analytes

  • Boldenone
  • Zeranol
  • Ractopamine
  • Corticosteroids
  • Nandrolone
  • Stilbenes
  • Trenbolone
  • Stanozolol
  • Beta-Agonists (Clenbuterol)

Endocrine Array Quality Controls

Therapeutic Drug Quality Control

Human based quality control designed for use in the routine monitoring of both accuracy and precision. Three levels of control are supplied with assayed target values and ranges provided for 4 analytes.

Features & Benefits

  • Lyophilised for enhanced stability
  • Assayed values available for Randox Biochip systems
  • Stable to expiry date at 2oC – 8oC
  • Reconstituted stability of 7 days at 2oC – 8oC or 21 days at -20°C
DescriptionSizeAnalytesCat No 
Endocrine Array Controls3 x 3 x 1ml4EV3713 
Endocrine Array Calibrator Series9 x 1ml4EV3712

Analytes

  • Cortisol
  • DHEA-Sulphate
  • 17αHydroxyprogesterone
  • Leptin

Cytokine Array IV Quality Control

Therapeutic Drug Quality Control

A multi-analyte quality control with target values and ranges provided for 5 analytes.

Features & Benefits

  • Lyophilised for enhanced stability
  • 100% human recombinant material
  • Stable to expiry date at 2°C – 8°C
  • Reconstituted stability of 7 days at 2°C – 8°C or 28 days at -20°C
  • Assayed values available for Randox Biochip systems
DescriptionSizeAnalytesCat No 
Cytokine Array IV Control3 x 3 x 1ml5CY5011

Analytes

  • Soluble Interleukin 2 receptor a (sIL-2Ra)
  • Soluble Interleukin 6 receptor (sIL-6R)
  • Soluble Tumour Necrosis Factor Receptor I (sTNFR I)
  • Soluble Tumour Necrosis Factor Receptor II (sTNFR II)
  • Matrix Metalloproteinase 9 (MMP-9)

Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie